Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia

Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yilin, Han, Linlin, Li, Shiyu, Hu, Tianyu, Xu, Zhiheng, Fan, Yun, Liang, Xiaoniu, Yu, Huan, Wu, Jianjun, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911758/
https://www.ncbi.nlm.nih.gov/pubmed/36759508
http://dx.doi.org/10.1038/s41531-023-00447-7
_version_ 1784885059201794048
author Tang, Yilin
Han, Linlin
Li, Shiyu
Hu, Tianyu
Xu, Zhiheng
Fan, Yun
Liang, Xiaoniu
Yu, Huan
Wu, Jianjun
Wang, Jian
author_facet Tang, Yilin
Han, Linlin
Li, Shiyu
Hu, Tianyu
Xu, Zhiheng
Fan, Yun
Liang, Xiaoniu
Yu, Huan
Wu, Jianjun
Wang, Jian
author_sort Tang, Yilin
collection PubMed
description Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of patients with PD-MCI (n = 31) was followed up for 4.1 ± 2.3 years. Compared with healthy controls, plasma GFAP levels were elevated in patients with PDD (adjusted P < 0.001) and PD-MCI (adjusted P = 0.013) and were negatively correlated with the Mini Mental State Examination (MMSE) score in PD participants. Plasma GFAP predicted MCI-to-dementia conversion with an AUC of 0.90, higher than NfL, Tau and pTau181. Our results support that plasma GFAP has potential value for distinguishing patients with PDD, and predicting MCI-to-dementia conversion in PD.
format Online
Article
Text
id pubmed-9911758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99117582023-02-11 Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia Tang, Yilin Han, Linlin Li, Shiyu Hu, Tianyu Xu, Zhiheng Fan, Yun Liang, Xiaoniu Yu, Huan Wu, Jianjun Wang, Jian NPJ Parkinsons Dis Article Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of patients with PD-MCI (n = 31) was followed up for 4.1 ± 2.3 years. Compared with healthy controls, plasma GFAP levels were elevated in patients with PDD (adjusted P < 0.001) and PD-MCI (adjusted P = 0.013) and were negatively correlated with the Mini Mental State Examination (MMSE) score in PD participants. Plasma GFAP predicted MCI-to-dementia conversion with an AUC of 0.90, higher than NfL, Tau and pTau181. Our results support that plasma GFAP has potential value for distinguishing patients with PDD, and predicting MCI-to-dementia conversion in PD. Nature Publishing Group UK 2023-02-09 /pmc/articles/PMC9911758/ /pubmed/36759508 http://dx.doi.org/10.1038/s41531-023-00447-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Tang, Yilin
Han, Linlin
Li, Shiyu
Hu, Tianyu
Xu, Zhiheng
Fan, Yun
Liang, Xiaoniu
Yu, Huan
Wu, Jianjun
Wang, Jian
Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title_full Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title_fullStr Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title_full_unstemmed Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title_short Plasma GFAP in Parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
title_sort plasma gfap in parkinson’s disease with cognitive impairment and its potential to predict conversion to dementia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911758/
https://www.ncbi.nlm.nih.gov/pubmed/36759508
http://dx.doi.org/10.1038/s41531-023-00447-7
work_keys_str_mv AT tangyilin plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT hanlinlin plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT lishiyu plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT hutianyu plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT xuzhiheng plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT fanyun plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT liangxiaoniu plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT yuhuan plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT wujianjun plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia
AT wangjian plasmagfapinparkinsonsdiseasewithcognitiveimpairmentanditspotentialtopredictconversiontodementia

Ejemplares similares